144 related articles for article (PubMed ID: 21035468)
1. Aberrantly silenced promoters retain a persistent memory of the silenced state after long-term reactivation.
Oyer JA; Yates PA; Godsey S; Turker MS
Mutat Res; 2011 Jan; 706(1-2):21-7. PubMed ID: 21035468
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
3. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
4. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
5. Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing.
Wu J; Wang SH; Potter D; Liu JC; Smith LT; Wu YZ; Huang TH; Plass C
BMC Genomics; 2007 May; 8():131. PubMed ID: 17524140
[TBL] [Abstract][Full Text] [Related]
6. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
7. Silencing of mouse Aprt is a gradual process in differentiated cells.
Yates PA; Burman R; Simpson J; Ponomoreva ON; Thayer MJ; Turker MS
Mol Cell Biol; 2003 Jul; 23(13):4461-70. PubMed ID: 12808089
[TBL] [Abstract][Full Text] [Related]
8. Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites.
Chen C; Yang MC; Yang TP
J Biol Chem; 2001 Jan; 276(1):320-8. PubMed ID: 11013250
[TBL] [Abstract][Full Text] [Related]
9. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Cameron EE; Bachman KE; Myöhänen S; Herman JG; Baylin SB
Nat Genet; 1999 Jan; 21(1):103-7. PubMed ID: 9916800
[TBL] [Abstract][Full Text] [Related]
10. Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture.
Stimson KM; Vertino PM
J Biol Chem; 2002 Feb; 277(7):4951-8. PubMed ID: 11733524
[TBL] [Abstract][Full Text] [Related]
11. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
12. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
13. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
Meng CF; Zhu XJ; Peng G; Dai DQ
World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
15. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.
Kondo Y; Shen L; Issa JP
Mol Cell Biol; 2003 Jan; 23(1):206-15. PubMed ID: 12482974
[TBL] [Abstract][Full Text] [Related]
16. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
[TBL] [Abstract][Full Text] [Related]
17. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4.
Yamada N; Nishida Y; Tsutsumida H; Goto M; Higashi M; Nomoto M; Yonezawa S
Br J Cancer; 2009 Jan; 100(2):344-51. PubMed ID: 19127263
[TBL] [Abstract][Full Text] [Related]
18. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.
Yang Q; Tian Y; Ostler KR; Chlenski A; Guerrero LJ; Salwen HR; Godley LA; Cohn SL
BMC Cancer; 2010 Jun; 10():286. PubMed ID: 20546602
[TBL] [Abstract][Full Text] [Related]
20. Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.
Chu Y; Wang Y; Zhang G; Chen H; Dowdy SC; Xiong Y; Liu F; Zhang R; Li J; Jiang SW
Cell Mol Life Sci; 2014 Sep; 71(17):3393-408. PubMed ID: 24531693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
